1.In vitro activity of β-lactamase inhibitors combined with different β-lac-tam antibiotics against multidrug-resistant Mycobacterium tuberculosis clinical strains
Jie SHI ; Dan-Wei ZHENG ; Ji-Ying XU ; Xiao-Guang MA ; Ru-Yue SU ; Yan-Kun ZHU ; Shao-Hua WANG ; Wen-Jing CHANG ; Ding-Yong SUN
Chinese Journal of Infection Control 2024;23(9):1091-1097
Objective To evaluate the in vitro effect of combinations of 5 β-lactam antibiotics with different β-lac-tamase inhibitors on the activity of multidrug-resistant Mycobacterium tuberculosis(MDR-TB),and identify the most effective combination of β-lactam antibiotics and β-lactamase inhibitors against MDR-TB.Methods MDR-TB strains collected in Henan Province Antimicrobial Resistance Surveillance Project in 2021 were selected.The mini-mum inhibitory concentrations(MIC)of 5 β-lactam antibiotics or combinations with different β-lactamase inhibitors on clinically isolated MDR-TB strains were measured by MIC detection method,and the blaC mutation of the strains was analyzed by polymerase chain reaction(PCR)and DNA sequencing.Results A total of 105 strains of MDR-TB were included in the analysis.MIC detection results showed that doripenem had the highest antibacterial activity against MDR-TB,with a MIC50 of 16 μg/mL.MIC values of most β-lactam antibiotics decreased significantly after combined with β-lactamase inhibitors.A total of 13.33%(n=14)strains had mutations in blaC gene,mainly 3 nu-cleotide substitution mutations,namely AGT333AGG,AAC638ACC and ATC786ATT.BlaC proteins Ser111 Arg and Asn213Thr enhanced the synergistic effect of clavulanic acid/sulbactam and meropenem on MDR-TB compared with synonymous single-nucleotide mutation.Conclusion The combination of doripenem and sulbactam has the strongest antibacterial activity against MDR-TB.Substitution mutations of BlaC protein Ser111 Arg and Asn213Thr enhances the sensitivity of MDR-TB to meropenem through the synergy with clavulanic acid/sulbactam.
2.Phenolic glycosides from the stems and twigs of Strychnos cathayensis and their biological activities
Qi-ming PAN ; Shuang-gang MA ; Yong LI ; Dan ZHANG ; Hua SUN ; Qi HOU ; Xiao-guang CHEN ; Shi-shan YU
Acta Pharmaceutica Sinica 2023;58(1):170-179
Fourteen compounds were isolated from the
3.Pathogenic characteristics of bloodstream infections in patients with hematological diseases and the impact of stem cell transplantation on them
CAI Ya-nan ; YE Li-yan ; ZHANG Guang-cun ; MA Wei ; GUO Ling ; WANG Li-feng ; MA Yan-ning ; YE Kun ; YANG Ji-yong
China Tropical Medicine 2023;23(4):392-
Abstract: Objective To investigate the epidemiological characteristics of pathogens causing bloodstream infection in hematology patients during treatment and to compare the effects of allogeneic hematopoietic stem cell transplantation (HSCT) on them, so as to provide evidence for the diagnosis and treatment of bloodstream infection. Methods A total of 292 cases with bloodstream infection in hematology wards of the PLA General Hospital were collected from 2017 to 2021, which were divided into HSCT group and N-HSCT group according to whether performed HSCT or not. The epidemiological characteristics and influence of pathogenic bacteria in blood stream infection were analyzed and compared between the two groups. Results A total of 362 strains of pathogenic bacteria were collected from 292 cases, including 106 strains in HSCT group (84 cases) and 256 strains in N-HSCT group (208 cases). Bloodstream infections were more common in acute myeloid leukemia (130/392, 44.52%), followed by non-Hodgkin's lymphoma (74/292, 25.34%). The rate of once bloodstream infection in HSCT group was higher than that in N-HSCT Group, but the rate of twice bloodstream infections in N-HSCT group was higher. Gram-negative Bacilli were the most common pathogens (56.08%), with Escherichia coli being absolutely dominant (109/362, 30.11%), followed by Klebsiella pneumoniae (39/362, 10.77%). Coagulase-negative staphylococci (CoNS) (107/362, 29.56%) were the most common Gram-positive cocci. The detection rate of fungi in HSCT group (10/106, 9.43%) was significantly higher than that in N-HSCT Group (3.52%). The drug resistance rate of the common pathogenic bacteria was at a high level, and there was a certain proportion of multi-drug resistant strains (except for Pseudomonas aeruginosa). The resistance rates of CoNS to penicillin, gentamicin, moxifloxacin, clindamycin and rifampicin in HSCT group were higher than those in N-HSCT Group. The resistance rate of Escherichia coli to piperacillin/tazobactam, cephalosporins and etapenem in HSCT group was significantly higher than that in N-HSCT group. Conclusions The pathogens of blood stream infection in hematology patients are complicated and various. It is difficult for clinical diagnosis and treatment to detect multiple infections and multiple pathogens. HSCT patients have a higher risk of fungal bloodstream infection and more multi-drug resistant strains detected. Therefore, the identification of bloodstream infection and multi-drug resistant strains associated with HSCT patients should prompt surveillance.
4.Quick guideline for diagnosis and treatment of novel coronavirus Omicron variant infection
Guang CHEN ; Tao CHEN ; Sainan SHU ; Xiaojing WANG ; Ke MA ; Di WU ; Hongwu WANG ; Yan LIU ; Wei GUO ; Meifang HAN ; Jianxin SONG ; Tonglin LIU ; Shusheng LI ; Jianping ZHAO ; Yuancheng HUANG ; Yong XIONG ; Zuojiong GONG ; Qiaoxia TONG ; Jiazhi LIAO ; Feng FANG ; Xiaoping LUO ; Qin NING
Chinese Journal of Clinical Infectious Diseases 2023;16(1):26-32
Novel coronavirus Omicron variant infection can cause severe illness and even death in certain populations. Omicron variant infection may lead to systemic inflammatory response, coagulation disorder, multi-organ dysfunction and other pathophysiological changes, which are different from other Novel coronavirus variants to a certain extent, so therapeutic strategies should not be the same. The National Medical Center for Major Public Health Events invited experts in fields of infectious diseases, respiratory medicine, intensive care, pediatrics and fever clinic to develop this quick guideline based on the current best evidence and extensive clinical practices. This quick guideline aims to standardize the diagnosis and treatment of novel coronavirus Omicron infection, and to improve the disease management abilities of clinicians.
5.Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5–24 Hours of Onset (ROSE-TNK): A Phase 2, Randomized, Multicenter Study
Lu WANG ; Ying-Jie DAI ; Yu CUI ; Hong ZHANG ; Chang-Hao JIANG ; Ying-Jie DUAN ; Yong ZHAO ; Ye-Fang FENG ; Shi-Mei GENG ; Zai-Hui ZHANG ; Jiang LU ; Ping ZHANG ; Li-Wei ZHAO ; Hang ZHAO ; Yu-Tong MA ; Cheng-Guang SONG ; Yi ZHANG ; Hui-Sheng CHEN
Journal of Stroke 2023;25(3):371-377
Background:
and Purpose Intravenous tenecteplase (TNK) efficacy has not been well demonstrated in acute ischemic stroke (AIS) beyond 4.5 hours after onset. This study aimed to determine the effect of intravenous TNK for AIS within 4.5 to 24 hours of onset.
Methods:
In this pilot trial, eligible AIS patients with diffusion-weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch were randomly allocated to intravenous TNK (0.25 mg/kg) or standard care within 4.5–24 hours of onset. The primary endpoint was excellent functional outcome at 90 days (modified Rankin Scale [mRS] score of 0–1). The primary safety endpoint was symptomatic intracranial hemorrhage (sICH).
Results:
Of the randomly assigned 80 patients, the primary endpoint occurred in 52.5% (21/40) of TNK group and 50.0% (20/40) of control group, with no significant difference (unadjusted odds ratio, 1.11; 95% confidence interval 0.46–2.66; P=0.82). More early neurological improvement occurred in TNK group than in control group (11 vs. 3, P=0.03), but no significant differences were found in other secondary endpoints, such as mRS 0–2 at 90 days, shift analysis of mRS at 90 days, and change in National Institutes of Health Stroke Scale score at 24 hours and 7 days. There were no cases of sICH in this trial; however, asymptomatic intracranial hemorrhage occurred in 3 of the 40 patients (7.5%) in the TNK group.
Conclusion
This phase 2, randomized, multicenter study suggests that intravenous TNK within 4.5–24 hours of onset may be safe and feasible in AIS patients with a DWI-FLAIR mismatch.
6.An alternative surgical technique for varicoceles: a preliminary experience of the microsurgical spermatic (distal end)-inferior or superficial epigastric vein anastomosis in symptomatic varicoceles associated with perineal pain.
Zi WAN ; Hai-Ming CAO ; Bi-Cheng YANG ; Yong GAO ; Li DING ; Peng LUO ; Guang-Wen YANG ; Lin MA ; Chun-Hua DENG
Asian Journal of Andrology 2022;24(6):624-627
Many therapies are effective in treating varicoceles, including dilation of the pampiniform plexus in males. The most common method of treatment is varicocelectomy. We aimed to assess an alternative technique (microsurgical spermatic [distal end]-superficial or inferior epigastric vein anastomosis) that preserves the normal blood flow pattern for varicocele treatment. We retrospectively analyzed 27 men with varicocele between October 2019 and July 2020. All patients underwent microsurgical spermatic (distal end)-superficial or inferior epigastric vein anastomosis. The prognosis was reviewed retrospectively with an additional survey conducted 3 months after surgery. The mean ± standard deviation of the age was 26.1 ± 7.3 years in patients with microsurgical spermatic (distal end)-superficial or inferior epigastric vein anastomosis. The maximum diameter of the varicocele vein, perineal pain score, sperm density, and forward movement of sperm improved over 3 months after surgery. Microsurgical spermatic (distal end)-superficial or inferior epigastric vein anastomosis is a safe and efficient surgical treatment for varicoceles.
Humans
;
Male
;
Adolescent
;
Young Adult
;
Adult
;
Varicocele/surgery*
;
Retrospective Studies
;
Microsurgery/methods*
;
Semen
;
Anastomosis, Surgical/methods*
;
Spermatozoa
;
Pain/surgery*
7.Immunogenicity of group A+C meningococcal polysaccharide conjugate vaccine in infants: A phase Ⅲ clinical trial study.
Li Li HUANG ; Xiao Min MA ; Hai Tao HUANG ; Zhi Qiang XIE ; Jin Bo GOU ; Yong Li YANG ; Xue WANG ; Wei ZHANG ; Wang Yang YOU ; Jie Bing TAN ; Li Feng XU ; Guang Wei FENG ; Tao ZHU ; Yanxia WANG
Chinese Journal of Preventive Medicine 2022;56(12):1728-1733
Objective: To evaluate the immunogenicity of group A+C meningococcal polysaccharide conjugate vaccine in infants under 2 years old. Methods: From March 2017 to June 2018, 1 932 healthy infants in Biyang County, Henan Province, who were not vaccinated with meningococcal meningitis vaccine and whose axillary temperature was ≤37.0 ℃, were recruited as participants. The 3 months and 6-11 months old infants were allocated to the experiment group and the control group in a ratio of 1∶1. Infants aged 12-23 months were allocated to the 1-dose group, the 2-dose group and the control group in a ratio of 1∶1∶1, with 276 infants in each group. The infants in the experiment group were intramuscularly injected with freeze-dried group A+C meningococcal polysaccharide conjugate vaccine to be evaluated, and infants in the control group received intramuscular injection of commercially available freeze-dried group A+C meningococcal conjugate vaccine. The venous blood of infants was collected 30 days before the first dose and after the last dose of inoculation, and the antibody seroconversion of each group was determined and compared. Results: The completion rate of immunogenicity study was 95.2% (1 839/1 932). Before inoculation, there was no statistical difference in the geometric mean titer and positive rate of group A+C antibodies between the experiment group and the control group in 3 months and 6-11 months old infants (all P values >0.05). The geometric mean titers and positive rate of group A antibodies in the 1-dose group were higher than those in the control group (all P values <0.05), but there was no statistical difference between the 2-dose group and the control group (all P values >0.05) in infants aged 12-23 months. After inoculation, the differences (95%CI) in the positive conversion rate of group A+C antibodies between the experiment group and the control group were -0.12% (-6.01%-5.77%) and 0.82% (-4.23%-5.86%) in the 3 months old infants. At the age of 6-11 months, the differences were 6.75% (1.71%-11.79%) and -4.32% (-8.73%-0.08%), respectively. At the age of 12-23 months, the differences were 1.02% (-3.80%-5.83%) and -4.40% (-7.79%- -1.01%) in the 2-dose group and -7.22% (-12.90%- -1.54%) and -18.61% (-23.75%- -13.46%) in the 1-dose group, respectively. The geometric mean titers of group A+C antibodies in the 3 months old infants were 48.50 and 63.12, respectively, which had no significant difference from the control group (43.02 and 57.99, respectively) (both P values <0.05). The geometric mean titers of group A+C antibodies in the 6-11 months and 12-23 months old infants were 84.09 and 92.51 (2-dose group), which were higher than those in the corresponding control group (43.10 and 61.83, respectively) (all P values <0.001). Conclusion: Group A+C meningococcal conjugate vaccine has good immunogenicity in infants under 2 years old.
Humans
;
Infant
;
Child, Preschool
;
Meningococcal Vaccines
;
Vaccines, Conjugate
;
Vaccination
;
Neisseria meningitidis
;
Polysaccharides
;
Antibodies, Bacterial
8.Metformin improves polycystic ovary syndrome and activates female germline stem cells in mice.
Chun-Hong WANG ; Qiang-Qiang WANG ; Ya-Shan SU ; Ya-Qun SUN ; Miao SUN ; Xin-Rui LIU ; Hui-Ming MA ; Guang-Yong LI ; Xiao-Li DU ; Rui HE
Acta Physiologica Sinica 2022;74(3):370-380
Polycystic ovary syndrome (PCOS) is a common disease caused by complex endocrine and metabolic abnormalities in women of childbearing age. Metformin is the most widely used oral hypoglycemic drug in clinic. In recent years, metformin has been used in the treatment of PCOS, but its mechanism is not clear. In this study, we aimed to investigate the effect of metformin on PCOS and its mechanism through PCOS mouse model. Female C57BL/6J mice aged 4-5 weeks were intragastrically given letrozole (1 mg/kg daily) combined with a high-fat diet (HFD) for 21 days to establish the PCOS model. After modeling, metformin (200 mg/kg daily) was intragastrically administered. One month later, the body weight and oral glucose tolerance test (OGTT) were measured. Hematoxylin eosin (H&E) staining was used to detect the pathological changes of ovary. The serum levels of anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), E2 and testosterone (T) were measured by ELISA. The expression of DDX4/MVH was detected by immunohistochemistry. DDX4/MVH and PCNA were co-labeled by immunofluorescence. The protein levels of DDX4/MVH, PCNA, cyclin D2, AMPK and mTOR were detected by Western blot. The results showed that after metformin treatment, the body weights of PCOS mice were gradually returned to normal, glucose tolerance was significantly improved, serum E2 levels were increased, while AMH, LH, T levels and LH/FSH ratio were decreased. Ovarian polycystic lesions were reduced with reduced atresia follicles. Furthermore, the number of proliferative female germline stem cells (FGSCs) and levels of proliferation related proteins (PCNA, cyclin D2) were significantly increased, and the p-mTOR and p-AMPK levels were markedly up-regulated. These results suggest that metformin treatment not only improves hyperandrogenemia, glucose intolerance and polycystic ovarian lesions in PCOS, but also activates the function of FGSCs. The underlying mechanism may be related to the phosphorylation of AMPK and mTOR. These findings provide new evidence to use metformin in the treatment of PCOS and follicular development disorder.
AMP-Activated Protein Kinases
;
Animals
;
Cyclin D2
;
Female
;
Follicle Stimulating Hormone/therapeutic use*
;
Humans
;
Luteinizing Hormone/therapeutic use*
;
Metformin/pharmacology*
;
Mice
;
Mice, Inbred C57BL
;
Oogonial Stem Cells/metabolism*
;
Ovarian Cysts/drug therapy*
;
Ovarian Neoplasms
;
Polycystic Ovary Syndrome/drug therapy*
;
Proliferating Cell Nuclear Antigen/therapeutic use*
;
TOR Serine-Threonine Kinases
9.Investigation of 68Ga-Labeled Magnetic Ferrite Nanoparticles PET/MRI Dual-Modal Imaging Probe
Wan-ru LI ; Guang-feng CHEN ; Ting YANG ; Si-qi HU ; Yuan YANG ; Xiao-li MA ; Yong ZHANG
Journal of Sun Yat-sen University(Medical Sciences) 2022;43(3):430-436
ObjectiveTo prepare 68Ga-labeled magnetic ferrite nanoparticles PET/MRI dual-modal imaging probe and evaluate the possibility of using it as a novel molecular probe for prostate cancer imaging. MethodsUsing superparamagnetic manganese iron oxide nanoparticles as the key component, fibroblast inhibitor and DOTA-NHS ester as the modification,along with chelating the positron radionuclide 68Ga, we prepared the nanoprobe 68Ga-DOTA-UMFNPs-FAPI-04. Characterization of nanoprobe and analysis of its cytotoxicity, radiochemical purity and stability were performed during the whole process. The observation of the distribution of nanoprobes in normal mice was performed. The effect of nanoprobes on MRI imaging on tumor-bearing mice was analyzed. ResultsAfter purification, the radiochemical purity of probe was 94%, also it had high stability. MRI T2 test showed that its T2 relaxation rate was about 39.02 mM-1·s-1. The bio-distribution in the normal mice showed that 68Ga-DOTA-UMFNPs- FAPI-04 had a higher uptake in liver and spleen. MRI imaging demonstrated that tumor could be observed clearly after probe injection in 30 minutes. ConclusionsWe have successfully constructed the PET/MRI dual-modal imaging probe 68Ga-DOTA-UMFNPs-FAPI-04. It has the characteristics of MRI T2 contrast agent and it also performs well in the MRI imaging of prostate tumors and has the potential of PET imaging. The study provides a new idea for constructing a multi-modal imaging probe for prostate cancer.
10.Screening and analysis of prognostic factors of repairing single missing tooth by autotransplantation of teeth.
Yong Qing LI ; Xiao Yong HUI ; Guang Jie XU ; Yuan Yuan MA ; Xia YANG ; Jie XU ; Qing Lin ZHU ; Zhou Ming ZHANG ; Xue WU ; Rui HOU
Chinese Journal of Stomatology 2022;57(5):495-502
Objective: To screen and analyze the factors affecting the prognosis of replacing single missing tooth by autograft tooth, so as to provide reference for clinical judgment of surgical prognosis. Methods: A total of 176 patients (188 teeth) underwent autotransplantation of teeth in the Department of Oral & Maxillofacial Surgery, School of Stomatology, The Fourth Military Medical University from January 2017 to December 2019, including 85 teeth of males and 103 teeth of females were involved. The age was (33.0±9.8) years (16-65 years). The possible factors affecting the prognosis of replacing single missing tooth by autograft tooth were summarized and grouped, and the clinical and imaging data were recorded and judged. The surgical records and photographic data from the patients' previous medical records were retrospectively analyzed. The survival analysis method was used for statistical analysis to screen out the factors affecting the cumulative survival rate of transplanted teeth. Results: The 5-year cumulative survival rate of 188 transplanted teeth was 88.4%. Univariate Log-Rank analysis showed that age (P<0.001), sex (P=0.008), smoking (P<0.001), position of recipient area (P<0.001), height of alveolar bone in recipient area (P<0.001), time of donor tooth in vitro (P<0.001), use of donor model (P<0.001) and initial stability (P<0.001) were significantly correlated with cumulative survival rate of transplanted teeth. Multivariate Cox proportional hazard regression analysis showed that smoking (β=-2.812, P=0.049), alveolar bone height (β=1.521, P=0.020), donor time (β=-2.001, P=0.019), use of donor model (β=1.666, P=0.034) and initial stability (β=-1.417, P=0.033) were significantly correlated with the cumulative survival rate of transplanted teeth. Conclusions: The prognosis of autogenous tooth transplantation can be predicted by smoking, height of alveolar bone in recipient area, time of donor teeth in vitro, use of donor model and initial stability. Good prognosis of transplanted teeth can be obtained by using donor model during operation, reducing the time of donor teeth in vitro, taking effective methods to restore alveolar bone height, maintaining good initial stability, and good oral health education after operation.
Adult
;
Female
;
Humans
;
Male
;
Prognosis
;
Retrospective Studies
;
Tooth/transplantation*
;
Tooth Loss
;
Transplantation, Autologous
;
Treatment Outcome
;
Young Adult

Result Analysis
Print
Save
E-mail